Clinical trials: ACS
Myocardial Infarction, Cardiovascular Death
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
This study is being carried out to see if a new drug called ticagrelor given twice daily in addition to the ASA therapy decreases the frequency of cardiovascular events (e.g., death from heart disease, heart attack, or stroke).
- Conditions
- Myocardial Infarction, Cardiovascular Death, Atherothrombosis, Stroke
- Trial name
- PEGASUS (NCT01225562)
- Testing
- Ticagrelor 90 mg, Ticagrelor 60 mg
- Where
- 826 sites in United States, Argentina and 29 more
- Volunteers
- 21,379 people
- Sponsor
- AstraZeneca
Non ST Elevation Myocardial Infarction
Clinical Effects of Eptifibatide Administration in High Risk Patients Presenting With Non-ST Segment Elevation Acute Coronary Syndrome (NSTE-ACS) Requiring Urgent Coronary Artery Bypass Graft Surgery in Short- and Long-Term Follow-up
1. INTRODUCTION Through last couple of years the number of patients treated for acute coronary event without persistent ST segment elevation in ECG has been growing.
- Trial name
- NCT01863134
- Testing
- Eptifibatide
- Where
- 6 sites in United States, Poland
- Volunteers
- 140 people
- Sponsor
- Medical University of Silesia
Acute Coronary Syndrome (ACS), High On-treatment Platelet Reactivity (HTPR)
The Effect of IV Cangrelor and Oral Ticagrelor Study
Major heart attacks are caused by a number of factors, the two major of which are furring up of a coronary artery with atheroma and then sudden clot formation on this area leading to a blockage and interruption of blood flow.
- Conditions
- Acute Coronary Syndrome (ACS), High On-treatment Platelet Reactivity (HTPR), Microvascular Obstruction (MVO), ST-segment Elevation Myocardial Infarction (STEMI)
- Trial name
- NCT02733341
- Testing
- Cangrelor, Ticagrelor
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- The Royal Wolverhampton Hospitals NHS Trust
Coronary Artery Disease (CAD)
GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation
After a stent procedure, it is common practice to prescribe anti-platelet medication to prevent the blood from clotting. The main objective of this study is to determine if there is a better medication strategy to prevent blood…
- Trial name
- NCT01813435
- Testing
- Ticagrelor, Acetylsalicylic Acid, Clopidogrel
- Where
- 130 sites in Australia, Austria and 16 more
- Volunteers
- 15,991 people
- Sponsor
- ECRI bv
Acute Coronary Syndrome, Depression
MBCT Delivered Via Group Videoconferencing for ACS Syndrome Patients With Depressive Symptoms
Brief Summary: The aim of this study is to explore the initial feasibility and acceptability of (a) Mindfulness-Based Cognitive Therapy (MBCT) adapted for ACS patients; (b) the group videoconferencing delivery medium; and (c)…
- Conditions
- Acute Coronary Syndrome, Depression, Myocardial Infarction, Unstable Angina
- Trial name
- NCT04231097
- Testing
- MBCT intervention for ACS patients
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Massachusetts General Hospital
Acute Coronary Syndrome (ACS)
Prasugrel Switching Study in Patients With Acute Coronary Syndrome (ACS) Who Underwent Percutaneous Coronary Intervention (PCI)
This Phase IV, multicenter trial is designed to assess the efficacy of prasugrel in preventing the formation of blood clots in Taiwanese patients with ACS who have been treated with PCI.
- Trial name
- NCT03672097
- Testing
- Prasugrel
- Where
- 10 sites in Taiwan
- Volunteers
- 204 people
- Sponsor
- Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company
Acute Coronary Syndrome (ACS)
Improving Medication Adherence Through Graphically Enhanced Interventions in Acute Coronary Syndromes
Coronary heart disease (CHD) is the leading cause of death in the United States. Most people who die from CHD die of a heart attack.
- Trial name
- IMAGE-ACS (NCT00399880)
- Testing
- Health literacy intervention
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- Vanderbilt University Medical Center
Acute Coronary Syndrome
MT1002 Phase II Study in ACS Patients With PCI
This is an open-label, sequential-dose escalation/de-escalation trial testing 3 dose levels of MT1002 in patients undergoing PCI due to ACS with NSTEMI.
- Trial name
- NCT04723186
- Testing
- MT1002 for Injection
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Acute Coronary Syndrome
Ranolazine Cardioprotection in PCI
The investigators will test if upfront dosing of Ranolazine can reduce myocardial biomarker release (CK-MB, Troponin) post percutaneous coronary intervention (PCI).
- Trial name
- NCT01767987
- Testing
- Ranolazine
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Harvey Hahn
Acute Coronary Syndrome, Depressive Symptoms
Comparison of Depression Identification After Acute Coronary Syndrome: Quality of Life and Cost Outcomes
The purpose of this study is to examine, in a randomized controlled trial, the benefits and costs of the American Heart Association's (AHA) advisory for depression screen and treatment of post-acute coronary syndrome patients.
- Trial name
- CODIACSQoL (NCT01993017)
- Testing
- Cognitive Behavioral Therapy (CBT), Antidepressant Medication, Standard Care
- Where
- 4 sites in United States
- Volunteers
- 1,501 people
- Sponsor
- Columbia University
Myocardial Infarction (MI), Acute Coronary Syndromes (ACS)
A Clinical Trial to Demonstrate the Efficacy of Cangrelor
The primary objective of this study is to demonstrate that the efficacy of cangrelor is superior, or at least non-inferior, to that of clopidogrel in subjects requiring PCI.
- Trial name
- PCI (NCT00305162)
- Testing
- Cangrelor (P2Y12 inhibitor), clopidogrel (oral P2Y12 inhibitor)
- Where
- United States
- Volunteers
- 8,882 people
- Sponsor
- The Medicines Company
ACS - Acute Coronary Syndrome
Positive Psychology for Acute Coronary Syndrome Patients
This is a randomized controlled pilot trial in approximately 50 acute coronary syndrome patients to determine if a 12 week, telephone-delivered, combined positive psychology-motivational interviewing intervention is feasible and…
- Trial name
- PEACE-IV (NCT03122184)
- Testing
- Positive Psychology + Motivational Interviewing, Motivational Interviewing Health Education
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- Massachusetts General Hospital
Acute Coronary Syndrome
Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS)
The purpose of this study is to compare the safety of two different dose regimens of unfractionated heparin (UFH) during a percutaneous coronary intervention (PCI) procedure in patients with UA (unstable angina)/NSTEMI (non ST…
- Trial name
- FUTURA/OASIS 8 (NCT00790907)
- Testing
- fondaparinux background and standard dose UFH, Fondaparinux background and low dose heparin, Open label fondaparinux
- Where
- 203 sites in United States, Argentina and 16 more
- Volunteers
- 3,235 people
- Sponsor
- GlaxoSmithKline
Depression
Treatment of Depression in Acute Coronary Syndrome (ACS) Patients
Emotional states of depression in association with ischemic heart diseases, such as myocardial infarction or unstable angina, are risk factors for subsequent cardiac events and mortality.
- Trial name
- TREATED-ACS (NCT00998400)
- Testing
- CBT in combination with WBT and life style modification
- Where
- 2 sites in Italy
- Volunteers
- 100 people
- Sponsor
- University of Bologna
Sickle Cell Anemia, Acute Chest Syndrome
Bi-Level Positive Airway Ventilation for Acute Chest Syndrome
Acute chest syndrome (ACS) is a frequent complication of sickle cell disease and is diagnosed by having findings on a chest x-ray and one of the following: chest pain, fever, or trouble breathing.
- Trial name
- NCT01589926
- Testing
- Bi-level positive airway pressure device
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Albert Einstein College of Medicine
Acute Coronary Syndrome
Treatment With Adenosine Diphosphate (ADP) Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome
The TReatment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) study is a prospective, observational longitudinal study to evaluate the real…
- Trial name
- TRANSLATE-ACS (NCT01088503)
- Testing
- ADP receptor inhibitors
- Where
- 186 sites in United States, Puerto Rico
- Volunteers
- 12,227 people
- Sponsor
- Eli Lilly and Company
Acute Coronary Syndromes (ACS)
Association Between SYNTAX Score and Leukoglycemic Index In Patients Wiht Acute Coronary Syndrome
This study looks at people who come to the hospital with acute coronary syndrome, a serious heart condition. When these patients first arrive, doctors take routine blood tests.
- Trial name
- NCT07276256
- Testing
- leukoglycemic index calculation
- Where
- Turkey (Türkiye)
- Volunteers
- 552 people
- Sponsor
- Kırıkkale University
Coronary Artery Disease, Acute Coronary Syndrome
Pharmacodynamic and Pharmacokinetic of Switching From Cangrelor to Prasugrel in ACS Patients Undergoing PCI
Cangrelor is an intravenous P2Y12 inhibitor utilized as a bridge to achieve adequate platelet inhibition until oral P2Y12 inhibitors achieve their full antiplatelet effects in patients undergoing coronary stenting.
- Trial name
- SWAP-6 (NCT04668144)
- Testing
- Cangrelor, Prasugrel
- Where
- United States
- Volunteers
- 359 people
- Sponsor
- University of Florida
Acute Coronary Syndrome (ACS)
PROSPECT II & PROSPECT ABSORB - an Integrated Natural History Study and Randomized Trial.
The present study has two components, an overall prospective observational study using multimodality imaging (PROSPECT II) that will examine the natural history of patients with unstable atherosclerotic coronary artery disease…
- Trial name
- P2 (NCT02171065)
- Testing
- ABSORB BVS
- Where
- Sweden
- Volunteers
- 902 people
- Sponsor
- Uppsala University
Acute Coronary Syndrome, Myocardial Infarction
An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome
The purpose of this study is to determine whether rivaroxaban in addition to standard care reduces the risk of the composite of cardiovascular death, myocardial infarction, or stroke in patients with a recent acute coronary…
- Conditions
- Acute Coronary Syndrome, Myocardial Infarction, Myocardial Ischemia, Unstable Angina
- Trial name
- NCT00809965
- Testing
- Rivaroxaban 2.5 mg, Rivaroxaban 5 mg, Standard of care
- Where
- 556 sites in United States, Argentina and 41 more
- Volunteers
- 15,526 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.